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Abstract 
Purpose: To isolate some compounds from the leaves and bark of Mimusops elengi, and examine 
them for their antibacterial and anti-inflammatory properties.  
Experimental: The compounds were isolated from the leaf and bark chloroform extracts using column 
chromatography, and characterized using physical and spectroscopic methods. The isolated 
compounds and their respective extracts were tested for antibacterial activity by micro-dilution 
antibacterial assay, and for anti-inflammatory activity by cyclooxygenase inhibitory assay.  
Results: of the compounds isolated include spinasterol (1), ursolic acid (2) and 3β, 6β, 19α, 23-
tetrahydroxyurs-12-en-28-oic acid (3) from the leaves; and taraxerol (4) and spinasterol β-D-
glucopyranoside (5) from the bark. A majority of the samples showed good activity against 
Staphylococcus aureus (9.7 ─ 78.0 μg/mL), while moderate activity was observed against Gram-
negative bacteria (78.0 ─ 156 μg/mL). Strong COX inhibition was observed for the leaf extract, and (1); 
selective COX-2 inhibition for (2) and (3); and selective COX-1 inhibition for bark extract, (4) and (5).  
Conclusion: This is the first report describing the anti-inflammatory potential of M. elengi on the basis 
of its isolated constituents. The results of this study support the traditional use of the plant as 
antibacterial and anti-inflammatory remedy. 
 
Keywords: Mimusops elengi, Sapotaceae, Steroids; Triterpenoids, Antibacterial, Anti-
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The family Sapotaceae comprises 35 – 75 
genera and approximately 800 species 
distributed pantropically with a few species in 
temperate regions. The genus Mimusops is 
native to the tropical parts of Africa and Asia. 
Mimusops elengi L. is an evergreen tree 30 feet 
tall, with a greyish brown fissured bark, wavy 
and dull green leaves, oblong berry fruit and 
creamy fragrant flowers. It is distributed in 
tropical and subtropical regions [1-3].    
 
 
M. elengi is known to possess various 
phytochemicals such as gallic acid esters, 
flavones, triterpenoids and steroids [2,4-5]. The 
volatile constituents of the flowers have also 
been reported [6]. 
 
Different parts of the plant are reported to be 
used in traditional medicine for the treatment of 
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microbial diseases such as diarrhoea, gum 
diseases, sore mouth, stomaches, ulcers, 
wounds and inflammation [1,3,7-9].  
 
Previous studies on M. elengi were mainly 
focused on the isolation and characterization of 
its phytochemical constituents, mostly from the 
stem bark, fruit, seeds and roots [10].  Moreover, 
most of the biological activities reported for M. 
elengi were on the extracts rather than the active 
constituents which might be responsible for its 
observed activities [1,9]. 
 
This paper reports the isolation and 
characterization of five constituents of the leaves 
and stem bark of M. elengi as well as the 
antibacterial and anti-inflammatory activities of 
the crude extracts and their isolated constituents. 
 
Previous phytochemical investigations of M. 
elengi had revealed the presence of 1 in the 
bark, heart-wood and seeds [11], 2 in the bark 
and fruit [12], and 4 in the roots and bark [12] 
(see Figure 1). Jahan et al. [4, 12] had also 
reported the occurrence of 1 and 2 in M. elengi 
but the plant part they examined was not 
specified. The present study showed 
conclusively the occurrence of 1 and 2 in the 
leaves, and confirmed the presence of 4 in the 
bark. Interestingly, 3, previously reported from 
Adina rubella, Dischidia esquirolii and Guettarda 
grazielae [13] and found in the leaves of M. 
elengi in the present study, has hitherto not been 
reported in a member of the Sapotaceae. 
Compound 5 was found for the first time in the 
bark of M. elengi although the C-3 epimer of 5 




Plant material  
 
The plant material was collected in April 2009 
from trees growing in the campus of Universiti 
Sains Malaysia and identified by one of the 
authors (F.A.). A voucher specimen (USM 9255) 
was deposited in the herbarium of the School of 
Biological Sciences, Universiti Sains Malaysia. 
  
Extraction and isolation 
 
Fresh leaves (3 kg) were macerated in 30 L of 
methanol-water (room temprature) (4:1 v/v). The 
extract was filtered and concentrated under 
reduced pressure at < 40 ºC to 1/10 of its original 
volume in a rotary evaporator, acidified with 
aqueous 2M H2SO4 to a pH of 2 ─ 3, and each 
500 mL portions of it extracted with chloroform 
(200 mL × 2, then 100 mL × 1) to give an extract 
(31 g). This extract was subjected to silica gel 
column chromatography, yielding ten fractions 
(F1 - 10) on elution with hexane/ethyl 
acetate/methanol (1/0/0 to 0/0/1 v/v/v). Fractions 
F2 (yellow oil, 1.3 g), F3 (green solid, 1.1 g) and 
F7 (green solid, 1.6 g) were rechromatographed 
to yield sub-fractions F2A-C, F3A-E and F7A-E, 
respectively. F2B (0.1 g), which eluted with 
hexane-ethyl acetate (8/2 v/v), yielded 1 (20 mg, 
6.6 × 10-4 %) upon recrystallization from diethyl 
ether. F3C (0.2 g), which eluted with hexane-
EtOAc (7/3 v/v), afforded 2 (25 mg, 8.3 × 10-4 %) 
upon recrystallization from methanol. F7C (0.34 
g), which eluted with EtOAc, gave 3 (32 mg, 1.0 
× 10-3 %) upon recrystallization from methanol.   
 
Fresh bark (4 kg) was air-dried for two weeks at 
room temperature (28 ºC) to a weight of 1 kg, 
powdered, and 150 g each of the powdered 
material was first defatted for 4 h with hexane in 
a Soxhlet extractor, and then extracted for 8 h 
with CHCl3, yielding a combined CHCl3 extract of 
14 g. This extract was fractionated on a silica gel 
column using hexane/EtOAc/MeOH (1/0/0 to 
0/0/1 v/v/v) to yield six fractions (FB1 - 5). FB1 
and FB3 were rechromatographed on a silica gel 
column using a hexane/EtOAc gradient to afford 
sub-fractions FB1A and FB3C, respectively. 
FB1A, which eluted with hexane/EtOAc (9:1 v/v), 
yielded 4 (25 mg, 6.2 × 10-3 %) after 
recrystallization from CHCl3. FB3C, which eluted 
with hexane/EtOAc (7:3 v/v), gave 5 (35 mg, 8.7 
× 10-3 %) after recrystallization in pyridine. 
  
Identification of isolated compounds 
 
Infrared spectra were recorded on a Perkin-
Elmer 1330 spectrophotometer. Nuclear 
Magnetic Resonance spectra were obtained with 
a Bruker Avance 400 MHz spectrometer. 
Electron Impact and Fast Atom Bombardment 
mass spectra were recorded using an Agilent 
5975C MSD and a Thermo Finnigan MAT95XL 
mass spectrometer, respectively. 
 
Micro-dilution antibacterial assay 
 
Serial dilution technique [14] using a 96-well 
micro-plate, was employed to determine 
minimum inhibitory concentration (MIC) as a 
measure of antibacterial activity. Two-millitre 
cultures of two Gram-positive bacteria, namely, 
Bacillus subtilis (ATCC6633) and 
Staphylococcus aureus (ATCC12600), and three 
Gram-negative bacteria, namely, Escherichia coli 
(ATCC25922), Klebsiella pneumoniae 
(ATCC13883) and Pseudomonas stutzeri 
(ATCC17588), were separately prepared and 
placed in an incubator overnight at 37 °C. The 
overnight-cultures were diluted with sterile 
nutrient broth (Merck) (500 μL bacteria/50 mL 
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broth) to yield density of bacterial cells range of 
105 - 106 cell mL-1. The isolated compound and 
crude extract samples under investigation were 
re-suspended to a concentration of 5 mg mL-1 
with ethanol to yield a final concentration of 1.25 
mg mL-1 in the assay for the first well. For each 
of the five bacteria used, 100 μL of the tested 
samples were serially diluted two-fold with 100 
μL sterile distilled water in a sterile 96-well micro-
plate. A similar two-fold serial dilution of 
gentamicin sulphate (1 mg mL-1, Sigma) was 
used as positive control against each bacterium. 
One hundred μL of each bacterial culture were 
added to each well of the test samples, 
gentamicin sulphate (positive control), ethanol, 
water and nutrient broth (negative controls). The 
plates were covered and incubated overnight at 
37 °C. To indicate bacterial growth, 50 μL of 0.2 
mg mL-1 p-iodonitrotetrazolium violet (INT, 
Sigma) was added to each well and the plates 
incubated at 37 °C for 30 min. Bacterial growth in 
the wells was indicated by red colour, while clear 
wells indicate inhibition by the test substances. 
This assay was repeated three times. 
 
Cyclooxygenase inhibitor screening assay 
 
Evaluation of the anti-inflammatory activity of the 
isolated compounds was based on the inhibition 
of prostaglandin biosynthesis. This was 
assessed using COX inhibitor screening assay 
kit (no. 560131; Cayman Chemicals, USA). The 
assay directly measures PGF2α by SnCl2 
reduction of COX-derived PGH2 produced in the 
COX reaction. This assay is based on the 
competition between PGs and a PG-
acetylcholinesterase conjugate (a PG tracer) for 
a limited amount of PG antiserum. Because the 
concentration of the PG tracer is held constant 
while the concentration of PG varies, the amount 
of PG tracer that is able to bind to the PG 
antiserum will inversely be proportional to the 
concentration of PG in the well. 
 
The plate was washed to remove any unbound 
reagents and then Ellman's reagent (Sigma) was 
added to the well to yield a yellow colour. The 
intensity of the colour was determined 
spectrophotometrically at 420 nm using Micro 
Plate Reader. The assay for obtaining 100 % 
COX activity was performed with ethanol as 
solvent control. The test samples and 
indomethacin (positive control) (Sigma) were 
redissolved in ethanol at a concentration of 10 
mg mL-1 to yield final concentrations of 5, 2.5 and 
1.25 µg mL-1. The pre-incubation time between 
enzyme and inhibitor was 10 min with 2-min 
incubation in the presence of arachidonic acid at 
37 °C. Enzyme control was performed with COX-
1 and 2 that had been inactivated by placing 
them in boiling water for 3 min. Inhibition of PGE2 
production by the test compounds and 
indomethacin was calculated from the standard 
curve using Graph Pad Prism software, version 
3.00 for Windows. IC50 values were calculated 
from the concentration-inhibition response curve 
by regression analysis using Graph Pad prism 





The data obtained from all experiments were 
expressed as mean ± standard error (SEM). 
Statistical difference between treatments and 
control were evaluated by one-way analysis 
(ANOVA) followed by Tukey’s multiple 







Spinasterol (stigmasta-7, 22(E)-dien-3β-ol) (1): 
m.p. 152-154ºC; : +12.4º (c 0.012, CHCl3); 
IR (KBr): 3426, 2956, 2869, 1637, 1456, 1382, 
1040, 970 cm-1; MS (FAB, 70 eV): m/z (%) = 413 
[M + H+] (15), 395 (22), 271 (26), 255 (10), 83 
(100), 69 (60); 1H NMR (400 MHz, CDCl3): 0.55 
(3H, s, H-18); 0.81 (3H, m, H-26), 0.84 (3H, d, J 
= 6.4 Hz, H-27), 1.00 (3H, d, J = 7.0, H-21), 3.60 
(1H, m, H-3), 5.04 (1H, dd, J = 15.5, 8.0 Hz, H-
23), 5.17 (2H, dd, J = 15.5, 8.0 Hz, H-7, H-22); 
13C NMR (100 MHz, CDCl3): 37.5 (C-1), 32.2 (C-
2), 71.4 (C-3), 38.4 (C-4), 40.6 (C-5), 30.0 (C-6), 
117.8 (C-7), 139.9 (C-8), 49.8 (C-9), 34.6 (C-10), 
21.9 (C-11), 39.8 (C-12), 43.6 (C-13), 55.5 (C-
14), 23.4 (C-15), 28.9 (C-16), 56.3 (C-17), 12.6 
(C-18), 13.4 (C-19), 41.2 (C-20), 21.7 (C-21), 
138.5 (C-22), 129.8 (C-23), 51.6 (C-24), 31.8 (C-
25), 19.2 (C-26), 21.5 (C-27), 25.8 (C-28), 12.4 
(C-29) [4]. 
 
Ursolic acid (3β-hydroxyurs-12-en-28-oic acid) 
(2): m.p 239-242 ºC; : +70.3º (c 0.025, 
MeOH); IR (KBr): 3428, 2927, 2870, 1692, 1457, 
1030 cm-1; MS (EI, 70 eV): m/z (%) = 456 M + (3), 
248 (100), 219 (8), 203 (44), 133 (31); 1H NMR 
(400 MHz, C5D5N): 0.88 (3H, s, H-25), 0.95 (3H, 
d, J = 6.5 Hz, H-29), 1.00 (3H, d, J = 6.5 Hz, H-
30), 1.04 (3H, s, H-26), 1.11 (3H, s, H-27), 1.24 
(3H, s, H-27), 3.44 (1H, dd, J = 10.0, 6.0 Hz, H-
3), 5.48 (1H, t, J = 5.0 Hz, H-12); 13C NMR (100 
MHz, C5D5N): 38.9 (C-1), 28.1 (C-2), 78.6 (C-3), 
39.4 (C-4), 55.7 (C-5), 18.4 (C-6), 33.3 (C-7), 
39.7 (C-8), 48.6 (C-9), 37.0 (C-10), 23.3 (C- 11), 
125.8 (C-12), 138.6 (C-13), 42.2 (C-14), 28.1 (C-
15), 24.3 (C-16), 48.6 (C-17), 53.3 (C- 18), 39.4 
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(C-19), 39.7 (C-20), 30.7 (C-21), 37.1 (C-22), 
27.7 (C-23), 15.3 (C-24), 15.0 (C- 25), 16.7 (C-
26), 23.0 (C-27), 180.6 (C-28), 16.0 (C-29), 20.5 
(C-30) [15]. 
 
3β, 6β, 19α, 23-Tetrahydroxyurs-12-en-28-oic 
acid (3): m.p. 250-252 ºC; : +13.2º (c 
0.025, MeOH); IR (KBr): 3440, 2927, 2870, 1687, 
1461, 1032 cm-1; MS (EI, 70 eV): m/z (%) = 505 
[M + H+] (3), 248 (10), 203 (15); 1H NMR (400 
MHz, C5D5N): 1.11 (3H, d, J = 6.3 Hz, H-30), 
1.47 (3H, s, H-29), 1.69 (3H, s, H-25), 1.71 (3H, 
s, H-24), 4.03 (1H d, J = 10.4 Hz, H-23a), 4.25 
(1H, dd, J = 11.5, 4.3 Hz, H-3), 4.37 (1H, d, J = 
10.4 Hz, H-23b), 5.06 (1H, br s, H-6), 5.67 (1H, 
br s, H-12); 13C NMR (100 MHz, C5D5N): 41.3 (C-
1), 27.1 (C-2), 73.6 (C-3), 44.1 (C-4), 49.5 (C-5), 
67.9 (C-6), 41.5 (C-7), 39.9 (C-8), 48.4 (C-9), 
37.0 (C-10), 24.2 (C-11), 128.6 (C-12), 139.4 (C-
13), 42.7 (C-14), 29.4 (C-15), 26.5 (C-16), 48.4 
(C-17), 54.8 (C-18), 72.9 (C-19), 42.5 (C-20), 
27.7 (C-21), 38.6 (C-22), 67.3 (C-23), 14.8 (C-
24), 17.6 (C-25), 18.4 (C-26), 24.9 (C-27), 180.9 
(C-28), 27.3 (C-29), 16.9 (C-30) [16]. 
 
Taraxerol (13α-methyl-27-norolean-14-en-3β-ol) 
(4): m.p. 276-278 ºC; : +7.4º (c 0.012, 
CHCl3); IR (KBr): 3484, 2933, 2865, 1641, 1473, 
1036 cm-1; MS (EI, 70 eV): m/z (%) = 426 M + 
(26), 411 (20), 393 (5), 302 (55), 287 (50), 204 
(100), 135 (40), 69 (30); 1H NMR (400 MHz, 
CDCl3): 0.84 (3H, s, H-27), 0.95 (3H, s, H-29), 
0.97 (3H, s, H-18), 1.11 (3H, s, H-27), 3.20 (1H, 
dd, J = 9.7 Hz, H-3), 5.55 (1H, dd, J = 8.1, 4.0 
Hz, H-15); 13C NMR (100 MHz, CDCl3): 38.1 (C-
1), 27.5 (C-2), 79.4 (C-3), 39.3 (C-4), 55.9 (C-5), 
19.1 (C-6), 35.5 (C-7), 39.1 (C-8), 49.1 (C-9), 
36.1 (C-10), 17.9 (C-11), 37.0 (C-12), 37.9 (C-
13), 158.4 (C-14), 117.2 (C-15), 38.1 (C-16), 
38.3 (C-17), 49.6 (C-18), 41.7 (C-19), 29.1 (C-
20), 34.0 (C-21), 33.4 (C-22), 28.3 (C-23), 15.8 
(C-24), 15.8 (C-25), 30.2 (C-26), 26.3 (C-27), 
30.3 (C-28), 33.3 (C-29), 21.7 (C-30) [17]. 
 
Spinasterol β-D-glucopyranoside (5): MP: 282-
285 ºC; : 16.4º (c 0.015, MeOH/CHCl3); IR 
(KBr): 3406, 2955, 2871, 1644, 1444, 1028 cm-1; 
MS (EI, 70 eV): m/z (%) = 574 M + (3), 412 (10), 
397 (30), 273 (20), 255 (40), 229 (19), 83 (85), 
55 (100); 1H NMR (400 MHz, C5D5N): 0.58 (3H, 
s, H-18), 1.09 (3H, d, J = 6.5), 4.06 (1H, m, H-3), 
4.42 (1H, d, J = 9.5, H-6’a), 4.60 (1H, d, J = 9.5, 
H-6’b), 5.04 (1H, m, H-23), 5.04 (1H, m, H-1’), 
5.19 (2H, dd, J = 15.0, 8.0 Hz, H-7, H-22); 13C 
NMR (100 MHz, C5D5N): 37.4 (C-1), 30.1 (C-2), 
77.2 (C-3), 34.6 (C-4), 40.3 (C-5), 30.1 (C-6), 
118.0 (C-7), 139.7 (C-8), 49.7 (C-9), 34.8 (C-10), 
21.9 (C-11), 39.7 (C-12), 43.6 (C-13), 55.4 (C-
14), 23.5 (C-15), 29.0 (C-16), 56.1 (C-17), 12.4 
(C-18), 13.2 (C-19), 41.3 (C-20), 21.8 (C-21), 
138.8 (C-22), 129.7 (C-23), 51.6 (C-24), 32.3 (C-
25), 19.3 (C-26), 21.4 (C-27), 25.8 (C-28), 12.7 
(C-29), 102.4 (C-1’), 75.5 (C-2’), 78.8 (C-3’), 71.9 




The antibacterial activity of the leaf and stem 
bark extracts, and isolated compounds 1 – 5, 
based on minimum inhibitory concentration 
(MIC), is shown in Table 1. Varying levels of 
activities were observed for the test samples 
against the five bacterial strains employed (Table 
1).  
 
Cyclooxygenase inhibitor screening activity: 
 
The inhibition of prostaglandin biosynthesis are 
indicated in Table 2. The highest concentration 
used was 5 µg/mL. Therefore, all IC50 values 
exceeding this value are expressed in the Table 





1  R = H,  





2  R1 = CH3, R2 = R3 = H 




















Figure 1: Structures of compounds 1-5 
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Table 1: Minimum inhibitory concentration (MIC, μg/mL) of the extracts, isolated compounds and gentamicin 
(control)  
 
Test sample Bacterial MIC (μg/mL) 
 Bs Ec Kp Ps Sa 
Leaf extract 156±0.0 156±0.0 78±0.0* 156±0.0 102±0.0 
1 58±0.1* 312±0.0 78±0.0* 195±0.2 9.7±0.0* 
2 468±0.2 468±0.2 312±0.0 468±0.3 243±0.1 
3 312±0.0 312±0.0 312±0.0 156±0.0 78±0.0* 
Bark extract 234±0.1 312±0.0 165±0.2 312±0.0 9.7±0.0* 
4 234±0.1 312±0.0 312±0.0 312±0.0 78±0.0* 
5 312±0.0 234±0.2 175±0.2 312±0.0 234±0.2 
Gentamicin (control) 0.3±0.1** 0.1±0.0** 1.7±0.1** 0.1±0.0** 0.01±0.0** 
Bs = Bacillus subtilis, Ec = Escherichia coli, Kp = Klebsiella pneuomoniae, Ps=Pseudomonas stutzeri, Sa=Staphylococcus 
aureus; values are expressed as mean ± S.E.M (n = 3); * p < 0.5; ** p < 0.1 
 
Table 2: Inhibition of prostaglandin biosynthesis by plant extracts, isolated compounds and indomethacin 
(positive control) 
  
Test sample % Inhibition (5 µg/mL) IC50 (µg/mL) 
 COX-1 COX-2 COX-1 COX-2 
Leaf extract 91** 63* 3.3±0.4 3.6±0.7 
1 93** 70* 4.4±0.8 3.7±0.2 
2 20 41* >5 >5 
3 12 47* >5 >5 
Bark extract 52* 23 4.5±0.3 >5 
4 50* 49* >5 >5 
5 78* 42* 3.2±0.7 >5 
Indomethacin (control) 95** 85** 3.1±0.3 4.6±0.6 




The leaf extract indicated strong inhibitory effects 
against the Gram-positive Staphylococcus 
aureus and the Gram-negative Klebsiella 
pneuomoniae, with MIC values of 102 and 78 
μg/mL, respectively, whereas moderate activity 
(156 μg/mL) was observed against the other 
strains. Staphylococcus aureus and Klebsiella 
pneumoniae. Compound 1 was the most active 
and showed strong inhibitory effects against 
Staphylococcus aureus, Bacillus subtilis and 
Klebsiella pneuomoniae, with MIC values of 9.7, 
58 and 78 μg/mL, respectively. Compound 3 
indicated strong activity (78 μg/mL) against 
Staphylococcus aureus and moderate activity 
(156 μg/mL) against Pseudomonas stutzeri. 
 
The bark extract showed strong activity (9.7 
μg/mL) against Staphylococcus aureus and 
moderate activity (165 μg/mL) against Klebsiella 
pneuomoniae. Compound 4 showed strong 
activity (78 μg/ml) against Staphylococcus 
aureus while compound 5 showed moderate 
activity (175 μg/mL) against Klebsiella 
pneuomoniae. All the isolated compounds were 
in accordance with the crude extracts in their 
antibacterial activity; all samples assayed 
showing reasonable activity against the tested 
strains. However, the observed activities of the 
leaf extract against Escherichia coli (156 μg/mL) 
and the bark extract against Staphylococcus 
aureus (9.7 μg/mL) were higher than the activity 
observed for the isolated compounds. This may 
be due to the synergistic effects of the bioactive 
agents in the crude extract.  
 
Both the leaf extract and compound 1 possessed 
strong inhibitory effects against prostaglandin 
biosynthesis produced by both COX-1 and COX-
2 enzymes. IC50 µg/mL values obtained for the 
leaf extract were 3.3 µg/mL and 3.6 µg/mL 
against COX-1 and COX-2,  respectively, while 
IC50 for t compound 1 was 4.4 µg/mL (COX-1) 
and 3.7 µg/mL (COX-2). Compounds 2 and 3 
showed selective COX-2 inhibition, but slightly 
higher inhibition was shown by compound 3. 
Bark extract showed moderate anti-inflammatory 
activity with selective COX-1 inhibition. 
Compound 4 showed moderate cyclooxygenase 
inhibitory activity, while compound 5 indicated 
the strongest COX-1 inhibitory activity, with IC50 
value of 3.2 µg/mL. IC50 for indomethacin 





The results obtained justify the reported anti-
inflammatory and antibacterial use of the plant in 
traditional medicine also and support its 
Ayurvedic medicinal use for ailments such as 
cephalalgia, diarrhoea, gum diseases, ulcers, 
sore teeth, stomach ache and wounds. Further 
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study is needed to determine its mechanisms of 
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